Comment on

• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

  Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Abifadel M, et al. Nat Genet. 2003 Jun;34(2):154-6. doi: 10.1038/ng1161. Nat Genet. 2003. PMID: 12730697
• Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

  Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Cohen J, et al. Nat Genet. 2005 Feb;37(2):161-5. doi: 10.1038/ng1509. Epub 2005 Jan 16. Nat Genet. 2005. PMID: 15654334
• Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.

  Stein EA, Raal F. Stein EA, et al. Annu Rev Med. 2014;65:417-31. doi: 10.1146/annurev-med-022613-090402. Annu Rev Med. 2014. PMID: 24422577 Review.
• Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

  Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, Cowan CA, Rader DJ, Musunuru K. Ding Q, et al. Circ Res. 2014 Aug 15;115(5):488-92. doi: 10.1161/CIRCRESAHA.115.304351. Epub 2014 Jun 10. Circ Res. 2014. PMID: 24916110 Free PMC article.